Genmab A/S Files IND for HuMax-TF-ADC

Published: Jul 18, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; July 18, 2013 – Genmab A/S (OMX: GEN) announced today the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start a Phase I dose escalation trial of HuMax-TF-ADC to treat multiple solid tumors. A maximum of 78 patients with cancer of the ovary, cervix, endometrium, bladder, prostate, head & neck, esophagus or lung that have failed or are not eligible for standard treatments will be enrolled in the study. The safety and tolerability of HuMax-TF-ADC will be established during a dose escalation part of the study. This will be followed by a cohort expansion part that will investigate longer-term safety and potential signs of anti-tumor activity.

Help employers find you! Check out all the jobs and post your resume.

Back to news